Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 100 Million+ Visitors
  • 75000+ Unique visitors per conference
  • 100000+ Page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Euro Antibiotics 2020

About Conference

“EURO ANTIBIOTICS 2020” invites all the participants from all over the world to attend “2nd Annual Congress and Exhibition on Antibiotics and Antimicrobial Resistance” to be held on July 09-10, 2020 | Geneva, Switzerland  which includes prompt  keynote presentationsOral talksPoster presentations and Exhibitions.

We establish a sequence of 1000+ Global Events comprehensive of 1000+ Conferences, 500+ Approaching and Previous Symposiums and Workshops in USA, Europe & Asia with provision from 1000 additional scientific societies and publishes 700+ Open access Journals which covers over 50000 distinguished personalities, alleged scientists as editorial board members.




Why to attend?

Antibiotics and antimicrobial Resistance 2020 is a stage to discuss and learn about the newest developments in the field of Antibiotics and Antimicrobial Confrontation as the world’s planning perverse regarding the insistence of new antibiotics as the antimicrobial resistance is growing day by day. Many advanced nations and Internati0nal health organizations are demanding to focus of the current situation and creati0n new policies to evade the adverse effects of Antibiotic resistance.

This conference creases researchers, academia, labs, Drug Manufacturers, g0vernment agencies, health professionals, hospitals, young investigat0rs, pharma and labs and presents their opinions thr0ugh key notes, and case study presentations. This conference lays a platform for all the detectives w0rking in the field of Antibiotics and antimicrobial to know the contemporary developments and the current situation of the conference.

2019 Highlights:

  • 300+ Participation (70 Industry: 30 Academia)
  • 10+ Keyn0te Speakers
  • 50+ Plenary Speakers
  • 20+ Exhibitors
  • 14 Inn0vative Educational Sessions
  • 5+ W0rkshops
  • B2B Meetings

Target Audience

  • Healthcare Students, Scientists, and professors
  • D0ctors
  • Microbiologist
  • Laboratories
  • Bacteriology Investigators
  • Faculty of bacteriology and infectious diseases
  • Medical C0lleges
  • Healthcare Ass0ciations and Societies
  • Commercial Entrepreneurs
  • Direct0rs, CEO’s of Organizations
  • Corporate Development Managers

C0nference Opportunities

  • Speaker Performances 
  • P0ster Display 
  • Symp0sium hosting (4-5 member team)         
  • Workshop organizing
  • For Researchers and Faculty Members

For Universities, Associations & S0cieties:

  • Ass0ciation Partnering
  • Collab0ration proposals          
  • Academic Joining   
  • Assembly Participation

For Students and Research Sch0lars

  • Poster C0mpetition (Winner will get Greatest Poster Award)        
  • Early Researcher Forum (YRF Award to the best presenter) 
  • Scholar Attendee        
  • Assembly Registrations     

For Business Delegates

  • Speaker Performances 
  • Symp0sium hosting    
  • Book Launch event    
  • Interacting opportunities       
  • Listeners participation

For Pr0duct Manufacturers

  • Exhibitor and Salesperson Booths
  • Sponsorships openings
  • Product presentation
  • Worksh0p establishing
  • Scientific Associating
  • Marketing and Netw0rking with customers




Track 1: Discovery of Antibiotics:

Antibiotics are a kind of antimicrobials used in cure and prevention of  bacterial infections. They may prevent or kill the development of bacteria. Numerous antibiotics are also operative against protozoans and fungi; some are toxic to animals and humans also, even when specified in therapeutic dosage. Antibiotics are not effective against viruses such as influenza  or common cold, and may be harmful when taken improperly. Physician’s necessity certify the patient has a bacterial infection before prescribing antibiotics.

Track 2: Pharmacology of Antibiotics:

Antibiotics form part of a broader variety of antimicrobial agents, a group which also includes antifungals, antivirals, antiprotozoal and disinfectants. This group is also known as chemotherapeutic agents. The conference is open for clinical pharmacology of antibiotics, Drug therapy, Pathophysiology, Pharmacokinetics and Pharmacodynamics, Drug screening, classification, synthesis and assays for therapeutic efficacy, Drug disposition, Regulations needed for the approval of antibiotics, Supplies for production of antibiotics, Clinical trials, Structure – Activity relationship, Antibiotic prophylaxis, Synthesis of antimicrobials, New methods of testing antimicrobial activity, Synergism between different types of antimicrobials, Design and testing of antimicrobial exteriors.

Track3: DifferentKindsofAntibiotics:
Antibiotics belong to a class of antimicrobials, a longer group which also comprises anti-viral, anti-fungal, and anti-parasitic drugs. The chief classes of antibiotics are beta-lactams which again include penicillincephalosporinmacrolidesfluoroquinolonetetracycline, and aminoglycosides.

Track 4: Antibiotics for Emerging and Re-Emerging Infections:

Antibiotic-resistant straining of pathogenic bacteria are progressively predominant in hospitals and the public. New antibiotics are desirable to battle these bacterial pathogens, but development in developing them has been slow. The meeting is open to deliberate on synthetic tailoring, discovery of new scaffolds, scheming screens that evade remembering old scaffolds, repurposing libraries of synthetic molecules for use as antibiotics, Roaming microbial niches for foods, molecular target assortment, cultivating collections to dazed resistance, Safety and efficacy, Vaccines available for the diseases, Phage’s and parasitic bacteriaEpidemiology and spread of microbes and resistance characters.

Track 5: The Appearance of Antimicrobial Resistance:

Antibiotic resistance mentions specifically to the resistance to antibiotics that happens in common bacteria that cause infections. The informal contact and effectiveness of Antibiotics controlled to overemployment in live-stock rising endorses bacteria to develop resistance. This controlled to widespread difficulties with antibiotic resistance. World Health Organization (WHO) categorized antimicrobial resistance as a severe threat and no lengthier a prediction for the future.  Antibiotic resistance is now amongst every part of the world and its moving everyone irrespective to the age. When infections develop resistant to first-line drugs, more expensive therapies must be used. A longer period of illness and action, often in hospitals, developments health care prices as well as the financial burden on families and societies. To assistance prevent the development of current and future bacterial resistance, it is significant to recommend antibiotics rendering to the principles of antimicrobial stewardship, such as signifying antibiotics only when they are required.

The US Centres for Disease Control and Prevention (CDC) said today that antibiotic-resistant pathogens sicken 2 million Americans a year and listed the three most urgent intimidations as Clostridium difficile, carbapenem-resistant Enterobacteriaceae (CRE), and Neisseria gonorrhoeae. Antibiotic-resistant microorganisms show a role in 23,000 demises each year, the CDC said.

Track 6: Antibiotics for Several Illnesses and Infections:                                      

Antibiotics are amongst the greatest frequently prescribed medications in modern medicineAntibiotics are impractical against viral infections. When you take antibiotics, follow the guidelines carefully. It is important to quality your medicine even if you sensation better. If you stop treatment too soon, some bacteria may endure and re-infect you. Do not save antibiotics for future or use someone else's prescription.

About 2 million Americans each year produce hospital-acquired infections (HAIs), succeeding in 99,000 deaths – the vast mainstream of which are due to antibacterial-resistant pathogens. Two common HAIs alone (sepsis and pneumonia) destroyed nearly 50,000 Americans and cost the U.S. health care scheme more than $8 billion in 2006. Based on studies of the charges of infections triggered by antibiotic-resistant pathogens against antibiotic-susceptible pathogens, the cost to the U.S. health care system of antibiotic resistant infections is $21 billion to $34 billion each year and more than 8 million extra hospital days.

Track 7: Antimicrobial Confrontation:

Antimicrobial h0stility happens when microbes such as bacteria, fungi, viruses, and parasites variation f0r insufficient to antimicrobial drugs such as antibiotics, antifungals, antivirals, antimalarial and anthelmintic. Deprived of functioning antimicrobials for reserve and action of infections, medical procedures such as organ transplantation, cancer chemotherapydiabetes organization and key operation become at very great risk. Antimicrobial confrontation is a complex problem that touches all of society and is driven by many interrelated factors. Single, inaccessible interventions have limited influence. There have been cumulative public calls for global shared action to address the danger, including a application for international treaty on antimicrobial resistance.

Track 8: Antibiotic Shortage: A Serious Safety Concern:

Antibiotic lack is of great apprehension to FDA and healthcare community as many of  the antibiotics were the sole drugs to treat certain antibiotic-resistant infections for definite infectious conditions. Drug lacks pose a serious task for health care institutions, often inquisitive with patient care. A common repetition during a drug shortage is to choice an alternate therapeutic; however, these agents often present trials and may create safety trepidations. Patient harms including adverse events and medication mistakes may happen. Patients may also file grievances because of drug shortages. The session is open to discuss on Manufacturing site difficulties, shortage of raw materials, low commercial inducements, absence of accepted manufacturers, Defect in packaging and labelling.

Track 9: Antibiotics in Various Industries:

Antibiotics requirement is used accordingly in humans and animals because both uses portion to the occurrence, persistence, and growth of resistant bacteria. Resistant bacteria in nourishment producing animals are of specific apprehension. Food animals play as a basis of resistant pathogens and battle appliances that can directly or indirectly result in antibiotic resistant infections in humans. Resistant bacteria may be transmitted to humans finished the foods we eat. Some bacteria have twisted resistant to more than one sort of antibiotic, which varieties it more difficult to treat the infections they cause. Sustaining the competence of antibiotic drugs is active to secluding human and animal health.

Track 10: Micro Organisms in Recent Drug Discovery:

Biodegradable microbes are a prominent s0urce of  drug discovery, and numerous microbial products, anti-tumor products, antibi0tics, immune suppressants and others are recycled regularly for human therapies. Most of these products were accessed from cultivable (<1%) environmental microbes, means that the big number of microbes were not targeted for drug discovery. With the start of new and developing technologies, we are poised to harvest novel drugs from the so-called 'uncultivable' microorganisms. Multidisciplinary way of linking different technologies can assist and reform drug discovery from unproductive microbes and inspect the existing cramp of technologies and situation to swamp such limitations that might further increase the promise of drugs from environmental microbes.

Track 11: Drug Discovery and Novel Delivery Technologies:

In the previous most drugs have been developed either by identifying the active ingredient from traditional remedies or by serendipitous finding. A new access has been to identify how disease and infection are controlled at the molecular and physiological level and to mark specific entities based on this knowledge. The process of drug discovery involves the identification of candidates, characterization, screening, synthesis, and assays for therapeutic efficacy. Expansion of an present drug molecule from an usual form to a novel delivery system can significantly advance its performance in terms of patient agreement, effectiveness and safety. These days, drug delivery corporations are betrothed in the expansion of frequent platform technologies to get ambitious advantage, extend patent life, and growth market share of their products. Formerly a composite has showed its value in these tests; it will begin the process of drug development former to clinical trials.

Track 12: Clinical Trials of Antibiotics:

Prescribing doctors are, increasingly, using clinical trial data as a main source of evidence for indication based medicine for the treatment of infectious diseases, as in other clinical disciplines. However, it may be difficult to extract from these data the statistics that is needed for the management of the individual patient. At the same time, clinical trial data have been used, seemingly satisfactorily, in the process of drug registration, and the pharmaceutical industry has spent increasingly large sums of money to satisfy the needs of this process. In the aspect of all these difficulties, variations in the way antibiotic clinical trials are considered and achieved are clearly necessary, though this must not tip the stability so far as to concentrate them less valuable for those who currently derive greatest benefit from them.

Track 13: Antibiotics and Mechanism of Action:

Antibiotics action typically falls within 0ne of 4 mechanisms, three of which contain the inhibition or directive of enzymes  involved in cell barrier biosynthesisnucleic acid metabolism  and overhaul, or  protein synthesis, correspondingly. The fourth mechanism includes the disruption of membrane structure. Many of these cellular purposes stressed by antibiotics are most active in increasing cells. Since there is often overlay in these purposes among prokaryotic bacterial cells and eukaryotic mammalian cells, it is not amazing that some antibiotics have also been found to be useful as anticancer agents.

Track 14: Antibiotics: Market Analysis & Business Opportunities:

The global systemic antibiotics market was respected at $39.6 billion in 2013 and is expected to reach $41.2 billion by 2020, at a CAGR of 0.8%. Since, 2005 this market is seen to produce at an annual rate of 6.6% until 2011. About various corporations,industrial antibiotic these days and there are several additional antibiotics present in the marketplace such as aminoglycoside antibiotics and it covers about 79% of the global demand. Furthermore, the other antibiotics such as penicillin have 8%, tetracycline 4%, erythromycin 7%, streptomycin 1% and chloramphenicol has 1 % market  

Track15: List of Generic Antibiotics and Brand Name Antibiotics: Amoxicillin,doxycycline,cephalexin,ciprofloxacin,clindamycin,metronidazole,azithromycin,trimethoprim, amoxicillin, levofloxacin. AugmentinFlagylFlagyl ER,Amoxil,Cipro,Keflex,BactrimBactrim DS,Levaquin,Zithromax,Avelox,Cleocin.

Track 16: Antimicrobial Peptides

Antimicrobial peptides also named  Host Defence Peptides  are p0rtion of the innate immune response f0und among all classes of life. AMPs have a broad spectrum of targeted organisms extending from viruses to parasites. These peptides are potent, broad spectrum antibiotics which prove potential as novel therapeutic agents. Unlike the majority of conventional antibiotics it seems that antimicrobial peptides frequently destabilize biological membranes, can form transmembrane channels, and may also have the ability to enhance immunity by functioning as Immunomodulatory.

Track 17: Antibiotic production and Delivery method

Antibiotic production can be gathered into three methods: natural fermentationsemi-synthetic, and synthetic. As more and more bacteria endure to grow resistance to currently produced antibiotics, research and development of new antibiotics continues to be important. In additi0n to survey and development into the manufacture 0f new antibiotics, repackaging delivery systems is imp0rtant to improving efficacy 0f the antibiotics that are currently produced. Improvements to this field have seen the ability to add antibiotics directly into entrenched devices, aerosolization of antibiotics for direct transfer, and grouping of antibiotics with non-antibiotics to recover outcomes.

Track 18: Microorganisms Producing Antibiotics

Antibiotic is one of the most significant commercially exploited secondary metabolites produced by bacteria, fungi and Streptomyces and hired in a wide range. Most of the antibiotics used today are from the microorganisms that live in soil. Bacteria are easy to isolate, culture, maintain and to recover their strain. The main producers of the   microbial metabolites, the actinobacteria, fungi and other filamentous bacteria, represent inexhaustible sources for the future.

Track 19: Applications of Antibiotics

Antibiotics are used commercially, hypothetically useful in medicine for activities other than their antimicrobial action. They are used as antitumor agentsenzyme inhibitors counting powerful hypocholesterolemic agents, immunosuppressive agents, and anti-migraine agents, etc. This session mainly is to focus on the application of anti-bacterials, antifungals, and anti-cancers with their clinical use to date, including the expansion history, side effects, and etc. The antibiotics remained categorized by their uses, structure types, and molecular appliances.

Track 20: Pharmacokinetics and Pharmacodynamics of Antimicrobial drugs

The pharmacodynamics of an antimicrobial drug narrates its pharmacokinetics to the time course of the antimicrobial effects at the site of the infection. Evidence 0f the drug's antimicrobial pharmacodynamics properties provides a additional balanced basis for determination of optimal dosing regimens in terms of the dose and the dosing interval than d0 the minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) resolute in vitr0. This meeting generally importance 0n pharmacokinetics, antimicr0bial pharmacodynamics, the significance 0f pharmacodynamics on the entrance of resistant bacterial subpopulations, and the expansion of pharmacodynamics divides for use in the project of trials of these drugs and in the treatment of infected patients.

Track 21: Veterinary Importance of Antibiotics

Antibiotics are used in livestock production for two simple reasons: disease treatment and disease prevention. Just like humans, animals are prone to bacterial infections. As in hominid medicine, antibiotics are used to commendably delight those infections. In livestock manufacture, antibiotics can also be used to stop disease. There are times in an animal’s life, such as weaning, where definite diseases can be very common. Antibiotics are sometimes used to stop these diseases from becoming established in the first place.

Track 22: Antibiotics for Oncology

An antibiotic is a chemical made by a microbe that antagonizes the development of other cells.  They decrease the viability and clonal expansion of cancer stem cells is of broad importance, as cancer stem cells are increasingly accepted as a distinct cell type that gives rise to therapy resistance, tumour recurrence and detached metastasis. Therapeutic anticancer antibiotics have develop an recognized dealing for definite types of cancer. These drugs bind specifically to main and metastatic cancer cells to block cell growth, while preventive effects on surrounding healthy cells. Antibiotic drugs kill malevolent cells by breaking the DNA in the cell nucleus and by oxidizing dangerous complexes which are necessary for the cell. Antibiotics are used against leukaemia, bladder cancer, testicular cancer, and sarcomas.

Track 23: Antibiotics Overuse and Resistance

Antibiotic higher use is when antibiotics are applied. when they're not needed. Antibiotics are 0ne of the great improvements in medicine. But overprescribing them has controlled to resistant bacteria (bacteria that are tougher to treat). Some germs that were once very receptive to antibiotics have become more and more resistant. Antibiotic overemployment is a important driver of antimicrobial resistance. Antibiotic resistance occurs when bacteria alteration in response to the use of these medicines. Antibiotic resistance occurs naturally, but misappropriation of antibiotics in humans and animals is accelerating the process. Antibiotic resistance leads to extended hospital vacations, higher medical costs and improved mortality.


Track 24: Antibiotic-resistant Bacterial infections

Antibiotics have been used to treat people with infectious diseases produced by bacteria. Though, definite antibiotics have been used so extensively and for so extended that some bacteria that cause disease have develop resistant to them, making these treatments less actual. Antibiotic resistance happens when the medicine mislays its ability to destroy bacteria. As a result, the organisms continue to produce and cause infection, even in the occurrence of the antibiotic.

Track 25: Genetics of Antibiotic Resistance

Developed bacterial antibiotic confrontation can consequence fr0m the mutation of usual cellular genes, the attainment 0f distant resistance genes, or a c0mbination 0f these two mechanisms. The highest collective resistance mechanisms empl0yed by bacteria include enzymatic degradation 0r alteration of the antimicrobial, alteration in the antimicrobial target site, reduced cell wall permeability to antimicrobials, and active efflux 0f the antimicrobial across the cell skin. The feast of mobile genetic rudiments such as plasmidstransposons, and integrons has importantly donated to the fast dissemination 0f antimicrobial resistance amongst several bacterial types of human and veterinary prominence.

Track 26: Clinical Trials of Antibiotics

There has been an growing use of antibiotics in all areas of medicine. Clinical trials to examination antibiotics are generally of a fewer than satisfactory quality. The main objective of original clinical trials, at least, is to provide the pharmaceutical company with adequate information to persuade the regulatory authority that the drug is effective, safe and well produced.

Track 27: Clinical and Economic Burden of Antibiotic Resistance

Evidence of the scientific and financial inspiration of antimicrobial resistance is valuable to effect programs and performance in healthcare facilities, to guide policy makers and subsidy agencies, to describe the forecast of individual patients and to rouse interest in emerging novel antimicrobial agents and therapies. There are a variability of significant subjects that must be careful when scheming or understanding lessons into the clinical and economic outcomes linked with antimicrobial confrontation. One of the most misunderstood issues is how to quantity cost appropriately. This conference primarily emphasis on selection of significant matters that necessity be measured when designing or interpreting studies of the clinical and economic outcomes related with antimicrobial resistance.

Track 28: New antibiotics and non-antibiotic approaches

New antibiotics essential to be established, which surgeons will be able to use when existing drugs no extended work. Non-antibiotic treatments can also decrease our requirement on antibiotics. The government inspires corporations to advance new drugs and treatments. New technologies can also help prevent infections.

Track 29: Current research in antibiotic resistance

Antibiotic overuse and misuse has managed to a increasing number of bacteria in humans, animals and the environment that are resilient to life-saving antimicrobial therapies. Crucial action is needed to stop the development of resistance, and to hasten new treatments for bacterial infection. Research comprises epidemiology of together Gram-negative and Gram-positive infections, genetic mechanisms of resistance, expansion and broadcast in the hospice setting, as well as the public, and antimicrobial stewardship.

Track 30: The Next Generation Approach of Antibiotics

As research into antibiotic resistance enlarges, it is important to accept an openly proactive approach to antibiotic resistance identification and investigation, as well as antibiotic therapy development. This practical approach involves using a combination of functional metagenomicsnext-generation sequencing and cutting-edge computational methods to monitor the evolution and dissemination of resistance before a given resistance cause appears in a pathogen or in the scientific location, as well as proactively increasing next-generation therapies that board these resistance causes. Recent improvements in the field highlight the promise that the next generation of resistome studies hold for describing and countering emerging resistance threats.





Some Aspects

Antibiotics Journals

The Journal of Antibiotics | Annals of Infections and Antibiotics | Journal of Antibiotics Research | Journal of Antimicrobial Chemotherapy | Journal of Infection and Public Health | International Journal of Antibiotics | The American Journal of Medicine | International  Journal of Infectious Diseases | Stamford Journal of Microbiology | Journal of Global Antimicrobial Resistance | Journal 0f Pharmaceutical Sciences | International J0urnal of Pharmaceutics | The Pharmaceutical J0urnal | Pharmaceutical Research | European Journal 0f Pharmaceutics and Bi0 pharmaceutics | M0lecular Pharmaceutics | European J0urnal 0f Pharmaceutical Sciences | Asian Journal of Pharmaceutics | J0urnal of Pharmacy and Pharmacology  | Indian Journal 0f Pharmaceutical Sciences | Journal 0f Pharmacy and Pharmaceutical Sciences | Drug Development and Industrial Pharmacy | Journal 0f Pharmacy Practice | American Journal 0f Pharmaceutical Education | International J0urnal of Drug Development & Research | J0urnal 0f Bioequivalence & Bioavailability | Journal 0f Bio analysis & Biomedicine | J0urnal of Pharmacogenomics & Pharmacoproteomics | Journal 0f Vaccines & Vaccination | J0urnal 0f Drug Metabolism & Toxicology | Drug Designing: 0pen Access.

Top Pharmaceutical Universities around the world:

Harvard University | University of Cambridge | University 0f California, San Francisco | University College London | University of North Carolina | Karolinska Institute | Yale University | King's College London | University of California, San Diego | Cardiff University | Stanford University | The Imperial College of Science, Technology and Medicine | The University 0f Manchester | The University of Texas | Utrecht University | The University 0f Dundee | Columbia University | Monash University | University 0f Oxford | Pierre and Marie Curie University | Medical University 0f Vienna | Rockefeller University | Uppsala University | University 0f Pennsylvania | University 0f Zurich | University 0f Tuebingen | The 0hio State University | Radboud University NijmegenNorwegian University 0f Science and Technology | Vanderbilt University | McGill University | University 0f Hamburg | University 0f Lausanne | University 0f Paris Descartes  | The University of Tokyo | University 0f California, BerkeleySwiss Federal Institute of Technology Zurich | Kyoto University | University 0f Wisconsin – Madison | University 0f Arizona |University 0f South Florida | University 0f Utah | China Pharmaceutical University

USA Pharmaceutical Universities

University 0f Southern California | CUNY York College | Purdue University | University 0f Wisconsin-Madison | Albany College 0f Pharmacy and Health Sciences | University 0f North Carolina | University 0f Colorado | 0regon State University | Nova South-eastern University | Massachusetts College 0f Pharmacy and Health Sciences | University 0f Florida College of Pharmacy | University 0f Michigan College of Pharmacy | Campbell University School of Pharmacy | University of Pittsburgh School of Pharmacy | University of Georgia College 0f Pharmacy | Temple University School of Pharmacy | Ernest Mario School of Pharmacy | Skaggs School of Pharmacy | Eugene Applebaum College 0f Pharmacy and Health Sciences | University 0f North Carolina | University 0f Minnesota | University 0f California—San Francisco  | University 0f  Michigan—Ann Arbor | University of Texas—Austin | Ohio State University | University of Illinois—Chicago | University 0f Kentucky | Purdue University |University of Florida | University 0f Maryland—Baltimore  | University of Pittsburgh  | University of Southern California |University 0f WashingtonUniversity of Wisconsin—Madison | University 0f Arizona | University 0f Iowa | University 0f Tennessee Health Science Center | University 0f Utah | University 0f Kansas | Virginia Commonwealth University | University at Buffalo | University of Colorado—Denver | Auburn University  | University 0f California—San Diego | University 0f 0klahoma | Northeastern University |

Asia Pharmaceutical Universities

Nanyang Technological University | Chulal0ngkorn University | T0h0ku University | T0ky0 Medical and Dental University | Kyushu University | Nagoya University | Hokkaido University | Sungkyunkwan University | University of Science and Technology 0f China | Pohang University 0f Science and Technology | Korea University | University Malaya  | Indian Institute 0f ScienceUniversity of Tokyo | National University of Singapore | Kyoto University | University 0f Hong Kong | Peking University | Seoul National University | National Taiwan University  | Osaka University | Tsinghua University | Chinese University of Hong Kong | Fudan University |The Hong Kong University 0f Science and Technology | Taipei Medical University | Mahidol University | Korea Advanced Institute 0f Science and Technology | Y0nsei University | Shanghai Jiao Tong University

Europe Pharmaceutical Companies

 M0rph0sys |  Novasep | Flen Pharma | Toxikon |  Zoetis | Pharmavize | Galapagos | Eurogentec | LinaTech | Stada | Synthon | Ferring Pharmaceuticals | Lonza | UBC | Leo Pharma | Saniona | DanDrit Biotechnology | Taconic Biosciences | West PharmaMylan | Astellas Pharma | Boehringer Ingelheim | Allergan | Takeda | Brist0l-Myers Squibb | Eli Lilly | Teva Pharmaceutical Industries | Amgen | AbbVie |Stada Arzneim | Carl Zeiss Meditec | Freudenberg medical | Emergent biosolutions | Aran biomedical | Norgine | Lexogen | Haplogen | Octimet Oncology | Anacura | AstraZeneca | Glax0SmithKline | Gilead Sciences | Merck | Sanofi | Roche | Pfizer |  Novartis | Bayer | J0hns0n and J0hns0n | QPS | Biocrates | ThioMatrix | Polymun Scientific | Croma-Pharma | Affiris | Aposcience | EverCyte| 0ctapharma | Teleflex Medical | Janssen Pharmaceuticals | L0nza | B0ne Therapeutics | Formac Pharmaceuticals | 0ncurious | San0fi Genzyme | Alexion | Baxter | Chemnovatic | CSL Behring | Custom Pharmaceuticals | Fujirebi0Europe | Galen Limited | Martindale Pharma | Novo Nordisk A/S  | Petrone Group | Purna Pharmaceuticals  | Shire | UCB Pharma | Uni-Pharma | Covidien | Fresenius Se | Fresenius Medical | Rhoen Klinikum

USA Pharmaceutical Companies

Lexicon Pharmaceuticals | Marathon Pharmaceuticals | Meyer Brothers Drug C0mpany | NovaBay Pharmaceuticals | Nephroceuticals | 0vation Pharmaceuticals |Peregrine Pharmaceuticals | Pharmaceutical Research and Manufacturers of America | Proteon Therapeutics | Quark PharmaceuticalsReliant Pharmaceuticals | Sagent Pharmaceuticals | Sucampo Pharmaceuticals | Tonix Pharmaceuticals | Verus Pharmaceuticals,Gilead Sciences | J0hnson & J0hnson | Pfizer | Abbott Laboratories | Brist0l Myers Squibb | Amgen | Biogen Idec | Celgine Corporation | Merck & Co | Eli Lilly | Acura Pharmaceuticals | Alexion Pharmaceuticals | AMRI Global | Apricus Biosciences | Bi0Cryst Pharmaceuticals | Bi0vista | Ceragenix Pharmaceuticals | Coherus Bi0Sciences | Dynax pharmaceuticals | Endo International plc| Ensemble Therapeutics | Fabre-Kramer Pharmaceuticals | Genentech | H. K. Mulford Company | Impax Laboratories | Insys Therapeutics | Jones Pharma | Kal0Bios Pharmaceuticals |

Asia  Pharmaceutical Companies

 Gland Pharma | Natco Pharma | Haffkine Biopharmaceuticals | Allergan | Taisho Pharmaceutical | Dainippon Sumitomo | Wakunaga Pharmaceutical | Dainippon Sumitomo | Santen | Chugai Pharma| Kissei Pharmaceutical | WaVe Life Sciences | Mitsubishi Tanabe Pharma | Astellas | AnGes | Kubota Pharmaceutical | 0hara Pharmaceutical | Daewon Pharma | Charles River Laboratories | 0xonc Development | Yungjin Pharmaceutical | Neopeutics | Austrianova Biotechnology | 3M | Clinuvel Pharmaceuticals | Micropoint Technologies | Sphaera Pharma | VolitionRx | China Chemical and Pharmaceutical C0mpany | Foresee Pharmaceuticals3-D Matrix | Agilent | BeiGene | BioDuro | China Biological Products | Fosun Pharma | Lumenis | MicroP0rt | Senju Pharmaceutical | Sihuan Pharmaceutical | Sinovac Biotech | DesigneRx Pharmaceuticals | Pharmadax | Denov0 Biopharma | BioMarin Pharmaceuticals | Invitrogen | WuXiApptec | AngioDynamics | SciGenom | Dishman Specialty Chemicals | Intas Pharmaceuticals | Zydus Cadila | Advinus Therapeutics

African Pharmaceutical Companies

Fresenius Kabi Distribution | Luced Agencies | Akacia Health | Roche Pharmaceuticals | Biotech Laboratories  | Allied Drug Company | Janssen-cilag | Teva Pharmaceuticals | Medimoc Sarl | Bayer International Service | Boehringer Ingelheim |Columbia Pharmaceuticals | Ultimate Sp0rt Nutrition | Astra Zeneca Pharmaceuticals | Resmed Pharmaceuticals | Servier Laboratories | Embassy Pharmaceuticals | Amalgamated Pharmaceuticals | New S Buys | Afrox Limited | Amka Pharmaceuticals | Astra Pharmaceuticals | Brunel Laboratoria | Dia-Kure Ltd | Eden Pharmaceuticals Prod | Geo Schwulst Laboratories | GM Pharmaceuticals | Hersol Manufacturing Laboratories | Intramed | Johnson & J0hnson | Kyron Laboratories | Merck Generics RSA | Novo N0rdisk | Pharma Natura | Pharmacare Ltd | Resmed Pharmaceuticals | S N Pharmaceuticals | Smith & Nephew Pharmaceuticals | Smithkline Beecham

Pharmaceutical J0bs

Research Associate & Research Scientist - FR&D in Trikona Pharmaceuticals Private Limited | Pharmacist - Pentagon Gl0bal Solutions Limited | QA/QC in MSN Laboratories | Sr. Executive/asst. Manager/manager-Pharma Techni in Arihant Inn0chem Pvt Ltd | Sr. Executive / Exe IPR Formulation- Leading Pharma in Harman Finochem Ltd | Apotex- Analytical R&D 0pportunity | Junior Research Fellow in South India Textile Research Association | Research & Development (F&D) in Zim Laboratories Limited | Sr Research Associate Formulations R&D in Celon Laboratories Ltd | Sr. Officer F & D (Pharmaceutics) in SMVA Consultants | Manager in Torrel Cos. Pvt. Ltd | Quality Assurance in Suven Life Sciences Ltd | Risk Management Plan  Manager in Novartis | Associate Global Trial Director in Novartis  | Product Manager - 0phthalmology | Cardio-Diabetes for Pharma company  | Brand Manager / Product Executive in Senses pharmaceuticals ltd | Stores Clerk in Arist0 Pharmaceuticals Pvt. Ltd. | Area Sales Manager in East West Pharma (Pvt) Ltd


Market Analysis

The worldwide Antibiotics market is valued at $6,727.29 million in 2014 and is relied upon to develop at a CAGR of 13.03% in the vicinity of  2014 and 2019. Expanding sickness weight of irresistible maladies and expanded subsidizing for social insurance consumption are the vital development drivers for this market amid the conjecture time frame. The pharmaceuticals request piece characterized the major share 0f the Antimicrobials advertise in 2014; while the sustenance claim portion is normal develop at the most bewildering CAGR in the neighbourhood of 2014 and 2019 in the universal Antibiotics cabinet. The worldwide scientific antimicrobials marketplace is predictable to spread USD 5.77 Billion by 2021 from USD 3.35 Billion in 2016, rising at a CAGR of 11.5% from 2016 to 2021. Market growth can be attributed to issues such as the technical progressions; rising occurrence of catching diseases and rising eruption of epidemics; increasing healthcare outflow across the world; and accumulative funding, research grants, and public-private savings in the field of life science researches.

Evolving regions such as Asia-Pacific (including Japan, China, and India) are predictable to developed the new revenue-generating compartments in the marketplace in the next five years. The Asia-Pacific market is projected to grow at the highest CAGR during the forecast period owing to the growing number of hospitals and clinical diagnostic laboratories in India and China,escalating research competences for the progress of ground-breaking and reasonable clinical Antibiotics testing procedures across India, China, and Japan; and increasing occurrences of infectious diseases.

Market Research:

Market research is vital to the development of the industrial market, and endures to be in demand. In 2018, we anticipate delivery of new editions of our report on Antimicrobials Testing in the Global emission.

Global Market Survey:

Antimicrobials scope was esteemed at over USD 24.3 billion in 2017 and will exceed USD 675.2 billion with 7.9% CAGR from 2017 to 2024. At Worldwide Market It is a sole blend of main and subordinate research, with validation and iterations, in order to minimalize nonconformity and current the most precise examination of the manufacturing.

Increasing mandate of  new  technologies will drive the biotechnology industry size.  we’ve seen wonderful development and alteration in the industrial diagnostics industry, mainly in the food safety sector expertise in all aspects of the market, desirable wide experience in business organization, strategy development and global business, Antibiotics test volumes, marketplace standards and methods used by food creators about the world, based on full interviews with more than 450 food production amenities in America, Europe and Asia, including Japan. Total test capacities have increased 128%, and testing for specific foodborne pathogens like Salmonella and E. coli grew at an even earlier rate.

The worldwide DNA sequencing market is predictable to reach USD 85.5 Million by 2025 from USD 310.1 Million in 2017 growing at a CAGR of 8.5% during the prediction period.

The global market for Food Antibiotics reached nearly $7.1 billion in 2017. This market is expected to grow to nearly $9.6 billion in 2017 and $15.7 billion by 2025, with a compound annual growth rate (CAGR) of 8.1% from 2017 to 2025.

Global Nanotechnology Market was esteemed at $216.2 billion in 2017 and $448.3 billion in 2017. The total market is expected to grow at a compound annual development rate (CAGR) of 19.3% from 2017 through 2025 and reach $828 billion by 2025.


Based 0n knowledge, the industry is segmented keen on tissue engineering besides regeneration, fermentation, PCR, nanotechnology, chromatography, DNA sequencing and cell based assay. In 2017, the tissue engineering and regeneration division accounted for maximum income and was cherished at over USD 11.3 billion. However, the nanotechnology, fermentation and cell based assay subdivisions will information moneymaking development owed to increasing R&D enterprises by frequent biotechnological and pharmaceutical companies.

The global clinical Antimicrobials market is respected at $6,727.29 million in 2014 and is predictable to grow at a CAGR of 13.03% between 2014 and 2019. Accumulative disease burden of infectious diseases and increased funding for healthcare expenditure are the vital growth drivers for this market during the forecast period. The pharmaceuticals submission partition accounted for the principal ration of the Antibiotics marketplace in 2014, whereas the food solicitation segment is expected produce at the maximum CAGR amongst 2014 and 2019 in the worldwide Antimicrobials marketplace.

Market Overview:

Numerous microorganisms are used in industrial Antibiotics, comprising laboratory-selected mutants, naturally occurring organisms, and hereditarily modified organisms (GMOs). Antimicrobials research and development is finding cumulative application in oil and gas administrations, the food and beverage industry, and environmental testing organizations.

In addition, the traditional R&D in the biopharmaceutical industry is seeing an upsurge, due to drug development research, which is plateful in the growth of the industrial Antibiotics market.

Increased request for nutraceuticals and other fermented merchandises further drives the importance of industrial application of Antimicrobials on a great scale. Such influences are obliging to determination the industrial marketplace.

However, in the market, there are numerous conflicts experiential regarding the practice of genetically modified organisms in food sources, which are expected to limit the development of the industrial Antibiotics market.


Past Conference Report

Antibiotics Resistance 2019

                                                                  Antibiotics Resistance 2019 past Conference Report

Thanks to all of our delightful Speakers, Conference Attendees and Traitors; Antibiotics resistance 2019 Conference was our best ever! 5th International Conference on Antibiotics & Antibiotic Resistance hosted by Conference Series was held during May 30-31, 2019 Orlando, Florida, USA with the theme “The Antibiotic Resistance Crisis: Causes and Threats” which got splendid response. With the support and guidance of Organizing Committee Members and Editorial Board Members and astonishing presentations of all participants this prominent event became more impressive. Conference Series would like to convey a great gratefulness to following eminent people, Organizing Committee Members and Keynote speakers.


  • Helieh S Oz,UK Medical Center  USA
  • Myung-Soo Kang,iNtRON Biotechnology ,South Korea
  • siham M Mahgoub,Alzahra Hospital Dubai,UAE
  • Johnelle R. Whipple,Reckitt Benckiser,USA
  • Kenneth M Bischoff,U.S. Department of Agriculture,USA
  • Rongshi Li,University of Nebraska Medical Center,USA
  • Akira Kaji,University of Pennsylvania,USA
  • Tore Midtvedt,Karolinska Institute,Sweden
  • Hideko Kaji,Thomas Jefferson University,USA
  • Ghassan Matar,American University of Beirut,Lebanon
  • Byungse Suh,Temple University School of Medicine,USA
  • Hartmut Derendorf,University of Florida,USA
  • Tadashi Shimamoto,Hiroshima University,Japan
  • Glenn S Tillotson,TranScrip Partners LLC,USA
  • John M Clerici,Tiber Creek Partners, LLC,USA
  • Suresh Joshi,Drexel University College of Medicine,USA

Consolidating Committee Memberships and Dominant Speakers who reinforced for the attainment of this occasion with maintainable enthusiasm for outstanding success of this protuberant session it is glad to proclaim next annual meeting “2nd Annual Congress on Antibiotics and Antimicrobial Resistance July 09-10”, Genewa Switzerland. We hopefulness your positive support will make next annual also one more majestic success event.



To Collaborate Scientific Professionals around the World

Conference Date July 09-10, 2020

For Sponsors & Exhibitors

[email protected]

Speaker Opportunity

Supported By

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by